Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2360585 | 0.92 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAPOLBGPR119CHRM2 | |
| SCHEMBL31131213 | 0.92 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAPOLBGPR119CHRM2 | |
| SCHEMBL9051469 | 0.88 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNAPOLBGPR119CHRM2 | |
| SCHEMBL3022437 | 0.86 | GAA (0.54) | SMN1; SMN2POLBCHRM1GAAL3MBTL1 | |
| SCHEMBL4768470 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAPOLBGPR119CHRM2 | |
| SCHEMBL31693351 | 0.84 | POLB (0.45) | SMN1; SMN2LMNAPOLBGPR119CHRM2 | |
| SCHEMBL2408813 | 0.84 | POLB (0.45) | SMN1; SMN2LMNAPOLBGPR119CHRM2 | |
| SCHEMBL31727552 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAPOLBGPR119CHRM2 | |
| SCHEMBL13744727 | 0.82 | LMNA (0.58) | SMN1; SMN2LMNAPOLBGPR119CHRM2 | |
| SCHEMBL7041340 | 0.82 | LMNA (0.58) | SMN1; SMN2LMNAPOLBGPR119CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4676922-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024263586-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | PAQ Therapeutics Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024189488-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | ASTRAZENECA AB (SE) | 2024-09-19 | — | — | WO | disclosed |
| EP-4168002-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-4050012-A1 | PYRIDONE BORONATES FOR THE PREPARATION OF INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-08-31 | — | — | EP | disclosed |
| EP-4019508-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| EP-1727782-A1 | METHOD OF PRODUCING AMINOPHENOL COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-12-06 | — | — | EP | disclosed |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2006-04-13 | — | — | US | disclosed |
| WO-2005092832-A1 | METHOD OF PRODUCING AMINOPHENOL COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | WO | disclosed |
| EP-1551798-A1 | NOVEL SULPHONES FOR INHIBITION OF GAMMA SECRETASE | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004031138-A1 | NOVEL SULPHONES FOR INHIBITION OF GAMMA SECRETASE | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| EP-1173170-A4 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1173170-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000059503-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| US-5939436-A | Five-membered heteroaromatic compounds as dopamine receptor subtype ligands | MERCK SHARP & DOHME LTD. (GB) | 1999-08-17 | — | — | US | disclosed |
| WO-1996021660-A1 | FIVE-MEMBERED HETEROAROMATIC COMPOUNDS AS DOPAMINE RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | SMN1; SMN2 4092/4885LMNA 890/4885POLB 2618/4885 |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | SMN1; SMN2 4092/4885LMNA 890/4885POLB 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.